GlaxoSmithKline LLC v. Natco Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: GlaxoSmithKline LLC (Delaware); TESARO, Inc. (Delaware); Merck Sharp & Dohme LLC (New Jersey)
  • Defendant: Natco Pharma Ltd. (India); Natco Pharma USA LLC (Delaware)
  • Plaintiff’s Counsel: McCarter & English, LLP
• Case Identification: 1:26-cv-00168, D. Del., 02/13/2026
• Venue Allegations: Venue is alleged to be proper as to Defendant Natco Pharma USA LLC because it is incorporated in Delaware. Venue is alleged to be proper as to Defendant Natco Pharma Ltd. because it is a foreign corporation, which may be sued in any judicial district.
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic version of the cancer drug Zejula® (niraparib) constitutes an act of infringement of two patents covering specific crystalline forms of the drug's active ingredient.
• Technical Context: The technology at issue relates to pharmaceutical chemistry, specifically a stable, non-hygroscopic crystalline solid form of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor used in oncology.
• Key Procedural History: The complaint states that Defendant Natco Ltd. submitted ANDA No. 221116 to the FDA and provided Plaintiffs with a notice letter dated January 8, 2026, which included a Paragraph IV certification alleging the patents-in-suit are invalid or will not be infringed. This lawsuit was filed within the 45-day statutory period, which may trigger a 30-month stay of FDA approval for the generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,091,459 - "Niraparib Compositions"

The Invention Explained

• Problem Addressed: The patent addresses the need for a stable solid form of the drug niraparib suitable for pharmaceutical development (U.S. Patent No. 11,091,459, col. 10:62-65). The specification notes that other salt forms, such as a hydrochloride salt, were found to be "highly hygroscopic," a property that can complicate manufacturing, storage, and drug product stability (U.S. Patent No. 11,091,459, col. 11:58-62).
• The Patented Solution: The invention is a specific crystalline form of niraparib tosylate monohydrate, designated "Form I," which is described as a "non-hygroscopic solid form having suitable solubility properties, as well as favorable physical and chemical stability" (U.S. Patent No. 11,091,459, col. 11:62-66). The patent claims compositions containing this Form I that are "substantially free" of other, less desirable crystalline forms, designated Form II and Form III (U.S. Patent No. 11,091,459, abstract; U.S. Patent No. 11,091,459, col. 2:4-8).
• Technical Importance: Identifying a stable, non-hygroscopic crystalline polymorph is a critical step in drug development, as it directly impacts a drug's manufacturability, shelf life, and consistency in oral dosage forms (U.S. Patent No. 11,091,459, col. 11:58-66).

Key Claims at a Glance

• The complaint asserts independent claim 1 Compl. ¶33
• Essential elements of independent claim 1 include:
  • A composition comprising crystalline Form I of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide tosylate monohydrate.
  • The composition must be "substantially free" of crystalline Form II and Form III of the same compound.
  • Crystalline Forms I, II, and III are each defined by characteristic diffraction angles in an X-ray powder diffraction (XRPD) pattern.
  • The term "substantially free" is explicitly defined within the claim as comprising "less than about 6% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II, and Form III."
• The complaint asserts dependent claims 20-24 and 26, which further limit the composition, for instance by specifying it is an oral dosage form or a capsule Compl. ¶33

U.S. Patent No. 11,673,877 - "Niraparib Compositions"

The Invention Explained

• Problem Addressed: The ’877 Patent, which is a continuation of the application that led to the ’459 Patent, addresses the same technical problem: the need for a stable, non-hygroscopic solid form of niraparib for pharmaceutical use (U.S. Patent No. 11,673,877, col. 11:58-62).
• The Patented Solution: The patented solution is identical to that of the ’459 Patent: compositions comprising crystalline Form I of niraparib tosylate monohydrate that are substantially free of Forms II and III (U.S. Patent No. 11,673,877, abstract; U.S. Patent No. 11,673,877, col. 2:4-8).
• Technical Importance: As with the ’459 Patent, this invention provides a stable crystalline form essential for creating a reliable oral drug product (U.S. Patent No. 11,673,877, col. 11:62-66).

Key Claims at a Glance

• The complaint asserts independent claims 1 and 11 Compl. ¶40
• Essential elements of independent claim 1 are substantively identical to claim 1 of the ’459 Patent, reciting a composition with crystalline Form I that is substantially free (<6% w/w) of Forms II and III, with all forms defined by their respective XRPD peaks.
• Essential elements of independent claim 11 include:
  • A method of treating a patient diagnosed with certain cancers (including ovarian, fallopian tube, and prostate cancer).
  • The method comprises administering a pharmaceutically acceptable dose of the crystalline Form I composition that is substantially free of Forms II and III, as defined in claim 1.

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is the "Natco ANDA Product," identified as generic niraparib tablet products in 100 mg, 200 mg, and 300 mg dosage strengths, for which Natco Ltd. seeks FDA approval via ANDA No. 221116 Compl. ¶2

Functionality and Market Context

• The complaint alleges that the Natco ANDA Product has the same active ingredient, dosage form, and strength as Plaintiffs' branded product, Zejula®, and is bioequivalent to it Compl. ¶28 The act of infringement alleged is the submission of the ANDA itself, which seeks approval to manufacture, use, and sell this generic product in the United States prior to the expiration of the patents-in-suit Compl. ¶33 Compl. ¶40
• The accused product is positioned to be a generic competitor to Zejula®, a commercial cancer therapy Compl. ¶2 Plaintiffs allege that Zejula® is a commercial embodiment of the patents-in-suit Compl. ¶24

Visual Evidence

• No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not contain a detailed claim chart. The infringement allegations are based on the premise that because the Natco ANDA Product is a generic version of and bioequivalent to Zejula®, which is alleged to practice the patents, the Natco ANDA Product will also practice the patents Compl. ¶24 Compl. ¶28

U.S. Patent No. 11,091,459 Infringement Allegations

U.S. Patent No. 11,673,877 Infringement Allegations

The allegations for independent claim 1 of the ’877 Patent are substantively identical to those for claim 1 of the ’459 Patent, as the claims are nearly identical.

• Identified Points of Contention:
  • Polymorphic Identity: A central factual question will be whether the Natco ANDA Product actually contains the specific crystalline polymorph defined as "Form I" in the patents. This will likely be determined through analysis of scientific data, such as XRPD, from Natco's product.
  • Polymorphic Purity: Assuming Natco's product contains Form I, a further factual question is whether it is "substantially free" of Forms II and III, as defined by the patents' explicit "less than about 6% (w/w)" limitation. The case may involve disputes over the methods used to measure the percentage of different polymorphs.
  • Induced Infringement: For the method of treatment claim (Claim 11 of the ’877 Patent), a point of contention may be whether Natco's proposed product label will specifically instruct or encourage use for the cancers recited in the claim, thereby meeting the legal standard for inducement.

V. Key Claim Terms for Construction

• The Term: "substantially free of Form II and Form III"

• Context and Importance: This term defines the required purity of the claimed composition. Infringement requires not only the presence of Form I but also the absence (below a specific threshold) of other forms. The dispute will likely center on whether the accused product meets this negative limitation.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party seeking a broader reading might focus on the term "about 6%," arguing it provides some flexibility beyond a strict numerical cutoff.
  • Evidence for a Narrower Interpretation: The patentee acts as its own lexicographer by explicitly defining the term within the claim itself: "wherein substantially free of Form II and Form III means the composition comprises less than about 6% (w/w) combined total weight for Form II and Form III..." (’459 Patent, col. 42:23-29; ’877 Patent, col. 42:24-30). This explicit definition provides strong evidence for a narrow construction tied directly to the 6% threshold.

• The Term: "crystalline Form I"

• Context and Importance: This term defines the specific polymorph of the active pharmaceutical ingredient. The infringement analysis for all asserted claims depends on whether the accused product contains this exact crystalline structure.

• Intrinsic Evidence for Interpretation:

  • Evidence for Interpretation: The patents do not provide a text-based definition but instead define Form I by reference to its objective, scientific properties. Specifically, the claims state that Form I is "characterized by an X-ray powder diffraction (XRPD) comprising diffraction angles at 2θ values of 9.5±0.2, 24.9±0.2, and 26.0±0.2 degrees" (’459 Patent, col. 42:12-16). Practitioners may therefore focus less on construing the term itself and more on the factual comparison between the XRPD pattern of the accused product and the peaks specified in the claims and illustrated in the patent figures (e.g., ’459 Patent, FIG. 1).

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Natco will actively induce infringement of both patents by encouraging distributors, healthcare providers, and patients to use the Natco ANDA Product for its intended (and allegedly infringing) purposes Compl. ¶36 Compl. ¶43 It also alleges contributory infringement, stating that Natco knows its product is especially made for an infringing use and is not a staple article of commerce Compl. ¶37 Compl. ¶44
• Willful Infringement: The complaint does not contain an explicit allegation of willful infringement.

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to several core scientific and legal questions:

• A primary issue will be one of polymorphic identity: Does the crystalline form of niraparib in Natco’s ANDA product exhibit the same X-ray powder diffraction pattern as the claimed "Form I," or does it utilize a different, non-infringing polymorph?
• A second critical evidentiary question will be one of compositional purity: Assuming Natco’s product contains Form I, does it also contain 6% or more of the other specified polymorphs (Forms II and III), thereby avoiding the "substantially free" limitation of the claims?
• Regarding the method of treatment claim, a key question for induced infringement will be evidence of intent: Does Natco’s proposed product label, as submitted to the FDA, provide instructions or recommendations that would lead healthcare providers and patients to administer the drug for the specific cancer indications recited in claim 11 of the ’877 Patent?